KRAS and colorectal carcinoma: Approximately 30–40% of colorectal cancers (CRC) harbor activating mutations in Kirsten Ras (KRAS) proto-oncogene, which encodes for a GTPase transductor protein downstream of epidermal growth factor receptor (EGFR) as part of the RAS/RAF/MAPK pathway1.